High suPAR levels predict risk of mortality during hospitalization in acute heart failure patients

Wed Mar 31 2021

Soluble urokinase-type plasminogen activator receptor strongly predicts global mortality in acute heart failure patients: insight from the STADE-HF registry

published in Future Science

The objective of this new study was to evaluate the prognosis performance of the biomarker suPAR on mortality and risk of readmission in acute heart failure patients.

Within the 95 patients included in the statistical analysis, the suPAR level was significantly higher in those who died at one month and one year, meaning that suPAR was proven to be highly predictive of the risk of mortality. There was no significant difference in readmission risk.

Heart failure is a major cause of hospitalization, morbidity, and mortality and thus an immense burden to healthcare systems.

Therefore, the outcomes of this study emphasize the importance of measuring suPAR in patients with suspected heart failure, to improve patient stratification.

High suPAR levels predict the risk of mortality in patients hospitalized for acute heart failure

– Huet et al, Future Science , March 2021

Read the study here


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPARnostic POC+


Point-of-care finger prick

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates